Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fortress Biotech Inc Series A P

6.08
+0.640311.77%
Post-market: 6.080.00000.00%16:07 EDT
Volume:26.74K
Turnover:156.59K
Market Cap:306.91M
PE:-2.26
High:6.28
Open:5.59
Low:5.49
Close:5.44
Loading ...

Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
01 Apr

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

GlobeNewswire
·
20 Mar

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

GlobeNewswire
·
17 Mar

Sun Pharma to Acquire Checkpoint Therapeutics

PR Newswire
·
10 Mar

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

GlobeNewswire
·
06 Mar

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

GlobeNewswire
·
28 Feb

Mustang Bio Announces Closing of $8 Million Public Offering

GlobeNewswire
·
10 Feb

Mustang Bio Announces Pricing of $8 Million Public Offering

GlobeNewswire
·
06 Feb

Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex

TipRanks
·
28 Jan

Mustang Bio Announces Reverse Stock Split

GlobeNewswire
·
14 Jan

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

PR Newswire
·
06 Jan

Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
17 Nov 2024

Fortress Biotech: Q3 Earnings Snapshot

Associated Press Finance
·
15 Nov 2024

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

GlobeNewswire
·
04 Nov 2024

Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m

Simply Wall St.
·
31 Oct 2024

Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares

GuruFocus.com
·
26 Oct 2024